4-1BB Is Expressed on CD45RAhiROhiTransitional T Cell in Humans

Garni-Wagner, B. A.; Lee, Zang H.; Kim, Yong Baek; Wilde, Charles E.; Kang, Chang-Y; Kwon, Byoung S.

doi:10.1006/cimm.1996.0095

Cited by 37 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such enhanced migration of the memory cells to sites of inflammation may play a role in the pathogenesis of RA (Maldonado et al, 2003). 4-1BB was expressed upon activation in the memory T cell populations in humans (Garni-Wagner et al, 1996). In the future studies, 4-1BB expression in the nave and the memory T cells from both synovial fluid and peripheral blood will be determined in different phases of RA.…”

Section: Discussionmentioning

confidence: 91%

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis

Jung

Choi²,

Choi³

et al. 2004

Exp Mol Med

View full text Add to dashboard Cite

Abbreviations: BD, Behcet's disease; RA, rheumatoid arthritis; s4-1BB, soluble 4-1BB; s4-1BBL, soluble 4-1BB ligand; SLE, systemic lupus erythematosus A bstract R heum atoid arthritis (R A ) is a m ultifactorial autoim m une disease w hose etiopathogenesis is not w ell understood. Although soluble (s) form s of 4-1BB (s4-1BB) and 4-1BB legand (s4-1BBL) have been detected in the sera of RA patients, their significance is not know n. W e com pared the serum levels of s4-1BB and s4-1BBL in RA patients w ith those in system ic lupus erythem atosus (SLE) and Behcet's disease (BD) patients. Serum levels of s4-1BB and s4-1BBL w ere significantly higher in RA patients com pared w ith healthy controls, SLE or BD patients, and the abundance w as correlated w ith disease severity in patients w ith RA. The serum levels of s4-1BB in RA patients w ere inversely corroborated w ith 4-1BB expression levels on activated T lym phocytes. In addition, there was a correlation betw een serum levels of s4-1BB and s4-1BBL. The augm ented secretion of s4-1BB and s4-1BBL levels into the serum m ay reflect the clinical sym ptom s of RA and levels of s4-1BB and s4-1BBL in sera at the tim e of diagnosis m ay be indicative of the severity and outcom e of RA.

show abstract

Section: Discussionmentioning

confidence: 91%

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis

Jung

Choi²,

Choi³

et al. 2004

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…However, later studies showed that 4-1BB is constitutively on a number of cells, albeit at low levels, including Foxp3 + Tregs and DCs (2,6,7). Activation with a number of agonists, such as cytokines (IL-2, IL-4), polyclonal activators (Con A and PHA), and cell surface molecules (anti-CD3 and anti-CD28), and promoters of Ca2 + induction and PKC activity (ionomycin and photbol myristate acetate), further enhance the expression of 4-1BB (2,6,7). 4-1BB is completely cloned, and its protein sequence is documented, revealing that it exists both as a 30kDa monomer, and as a 55 kDa dimer (5).…”

Section: -1bb: Discovery and Phenotypementioning

confidence: 99%

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

2014

Self Cite

View full text Add to dashboard Cite

Although considerable progress has been made in understanding how tumors evade immune surveillance, measures to counter the same have not kept pace with the advances made in designing effective strategies. 4-1BB (CD137; TNFRS9), an activation-induced costimulatory molecule, is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand (4-1BBL) has important implications in many clinical conditions, including cancer. In-depth analysis revealed that 4-1BB-mediated anti-cancer effects are based on its ability to induce activation of cytotoxic T lymphocytes (CTL), and among others, high amounts of IFN-γ. In this review, we will discuss the various aspects of 4-1BB-mediated anti-tumor responses, the basis of such responses, and future directions. [BMB Reports 2014; 47(3): 122-129]

show abstract

“…When T cells are activated by a variety of stimuli such as anti-CD3 mAb, concanavalin A (Con A), phytohaemagglutinin (PHA), interleukin (IL)-2, IL-4, anti-CD28 mAb, phorbol myristyl acetate (P), or ionomycin (I), 4-1BB is stably upregulated (Garni-Wagner et al, 1996;Kim et al, 2003;Pollok et al, 1995). 4-1BB is induced in human peripheral blood mononuclear cells (PBMCs) by DNA-damaging agents such as doxorubicin, bleomycin, and γ-irradiation (Chung et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Regulation of Mouse 4-1BB Expression: Multiple Promoter Usages and a Splice Variant

Kim

Kwon

2011

Molecules and Cells

Self Cite

View full text Add to dashboard Cite

The expression of 4-1BB has been known to be dependent on T cell activation. Recent studies have, however, revealed that 4-1BB expression is not restricted to T cells. We sought to determine the molecular basis for the differential gene expression. Here we report the expression pattern of two mouse 4-1BB transcripts, type I and type II. Whereas the type I transcript was specifically expressed on immune organ as previously reported, the type II transcript was ubiquitously expressed in tissues and various cell lines. However, both type I and type II transcript were highly induced on activated T cells. Primer extension assay of the two 4-1BB transcripts suggested that mouse 4-1BB had more than two transcripts. Using luciferase assay we have identified three promoter regions (PI, PII and PIII), which located on upstream region of second exon 1, first exon 1, and exon 2, respectively. In particular, the type I transcript was preferentially induced when naïve T cells are stimulated by anti-CD3 monoclonal antibody (mAb) since NF-κB specifically binds to the putative NF-κB element of PI. We have also shown that a splice variant, in which the transmembrane domain was deleted, could inhibit 4-1BB signaling. The splicing variant was highly induced by TCR stimulation. Our results reveal 4-1BB also has a negative regulation system through soluble 4-1BB produced from a splice variant induced under activation conditions.

show abstract

4-1BB Is Expressed on CD45RAhiROhiTransitional T Cell in Humans

Cited by 37 publications

References 0 publications

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis

Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

Regulation of Mouse 4-1BB Expression: Multiple Promoter Usages and a Splice Variant

Contact Info

Product

Resources

About